FDA litargirio warning
This article was originally published in The Rose Sheet
Executive Summary
Consumers should immediately stop all use of litargirio powder, which is commonly found in deodorant, foot fungicide and burn and wound treatment products, agency announces. FDA is working with the Consumer Product Safety Commission to alert public to risks of lead poisoning after ingestion or contact with skin. Powder is a traditional remedy popular in the Dominican Republic that does not have any proven health benefits and is particularly harmful to children, agency points out. Rhode Island Department of Health alerted FDA to product's dangers after several children using litargirio as deodorant were treated for lead poisoning...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.